<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409588</url>
  </required_header>
  <id_info>
    <org_study_id>17-2349</org_study_id>
    <nct_id>NCT03409588</nct_id>
  </id_info>
  <brief_title>Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy</brief_title>
  <official_title>Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study of Riociguat in patients with continued exercise intolerance at
      least 6 months following pulmonary endarterectomy (PEA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pulmonary arterial pressure</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include mPAP (mean pulmonary arterial pressure) measured by right heart catheterization (RHC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cardiac output</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include CO (cardiac output) mPAP/CO slope measured by right heart catheterization (RHC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pulmonary artery compliance</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include Pulmonary artery compliance measured by right heart catheterization (RHC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include change in 6 minute walk test (6 MWT) following 3 months of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) functional class</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include Change in New York Heart Association (NYHA) functional class following 3 months of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the University of California San Diego (UCSD) shortness of Breath Score</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Measurements include: Change in the University of California San Diego (UCSD) shortness of Breath Score following 3 months of study drug</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Thromboembolic Disease (CTED)</condition>
  <condition>Exercise Intolerance Post PEA Surgery</condition>
  <arm_group>
    <arm_group_label>Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adempas</intervention_name>
    <description>After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.</description>
    <arm_group_label>Study Drug</arm_group_label>
    <other_name>Riociguat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients who underwent PTE for Chronic thromboembolic pulmonary hypertension
             (CTEPH) at least six months prior to screening and report ongoing subjective exercise
             limitation,

          -  able to give consent

          -  able to perform a exercise protocol

        Exclusion Criteria:

          -  Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for
             CTEPH

          -  ongoing PAH-specific vasodilator therapy

          -  known contraindication to riociguat

          -  a physical limitation to completing an exercise protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Bull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Sottile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Cornwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheri Abbott, RN</last_name>
    <phone>303-724-7466</phone>
    <email>Cheryl.Abbott@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Abbott, RN</last_name>
      <phone>303-724-7466</phone>
      <email>Cheryl.Abbott@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Sottile, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Cornwell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Thromboembolic Disease</keyword>
  <keyword>CTED</keyword>
  <keyword>Treatment Post PEA surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riociguat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

